Cadila gets US warning for manufacturing violations - Daily News & Analysis

Zydus Cadila, Ahmedabad-based pharmaceutical company which is listed as Cadila Healthcare on Indian bourses, has received a warning letter from US health regulator, Food and Drug Administration (FDA) over violation of current good manufacturing practice (GMP) regulations for finished pharmaceuticals at its facility in the state.

Visit http://geicoinsuranceproducts.wordpress.com/ for GEICO Insurance Products News / Reviews.

The injectable drug plant of the group near Ahmedabad has not yet started production but the FDA issued the warning letter on violations identified at the new plant following a pre-approval inspection. On Wednesday, FDA updated a warning letter to the CMD of Zydus Group, Pankaj Patel, noting that in an inspection of the company’s facility at Moraiya near Ahmedabad, investigators identified violations of CGMP regulations for finished pharmaceuticals. The regulator inspected the plant between January 17 and February 3, 2011.

Cadila gets US warning for manufacturing violations - Daily News & Analysis